Five-year-old French biotech Cerenis Therapeutics SA pulled in its third major venture round, adding €40 million (US$51.9 million) in Series C funding to advance its lead program, HDL-mimetic CER-001, into Phase II testing in cardiovascular disease. (BioWorld International) Read More